"Zydus Cadila has received the final approval from the USFDA to market Doxycycline Hyclate Capsules USP, 50 mg and 100 mg," the company said in a regulatory filing.
It is a tetracycline antibiotic used for the treatment of a wide variety of bacterial infections, including those that cause acne.
"This medication is also used for prophylaxis of malaria," the filing said.
The capsules will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
The group has more than 195 approvals so far.